News
Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...
Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...
Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® ...
Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...
Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.
Decision makes Wegovy the first GLP-1 class therapy cleared for MASH, a liver condition that affects around 5 per cent of ...
The new approval allows the GLP-1 to be used to treat adults with the liver disease metabolic dysfunction-associated steatohepatitis (MASH) and liver scarring. Wegovy is the first GLP-1 to receive ...
Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form of liver disease, beating rival Eli Lilly & Co. to the US market for the ...
Novo Nordisk (NYSE: NVO) is quite the divisive stock among both investors and analysts these days. Although its high-profile ...
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results